

B9
cont

the antigenic peptide or the antigenic fusion protein, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.

CLAIMS:

B10

1. (Amended) An isolated antigenic peptide comprising an amino acid sequence consisting of SEQ ID NO: 4 that induces an anti-IgE immune response that does not cause anaphylaxis when administered to an animal.

2. (Amended) An isolated antigenic fusion protein comprising an amino acid sequence consisting of SEQ ID NO: 4 and a heterologous carrier protein that induces an anti-IgE immune response that does not cause anaphylaxis when administered to an animal.

7. (Amended) A pharmaceutical composition for inducing an anti-IgE immune response that does not cause anaphylaxis comprising one or more antigenic peptides consisting of an amino acid sequence of amino acid residues of a CH3 domain of an IgE molecule or a fragment thereof.

B11

8. (Amended) The pharmaceutical composition of claim 7, wherein at least one antigenic peptide consists of the amino acid sequence of SEQ ID NO: 4.

9. (Amended) A pharmaceutical composition for inducing an anti-IgE immune response that does not cause anaphylaxis comprising one or more antigenic fusion proteins consisting of an amino acid sequence of amino acid residues of a CH3 domain of an IgE molecule or a fragment thereof; and a heterologous carrier protein.

10. (Amended) The pharmaceutical composition of claim 9, wherein at least one antigenic fusion protein consists of the amino acid sequence of SEQ ID NO: 4.

11. (Amended) The pharmaceutical composition of claim 9, wherein the heterologous carrier protein is selected from the group consisting of KLH, PhoE, rmLT, TraT, and gD from BhV-1 virus.

39. (Amended) An isolated antigenic peptide comprising an amino acid sequence consisting of SEQ ID NO: 4 or a fragment thereof, that induces an anti-IgE immune response that does not cause anaphylaxis when administered to an animal.

40. (Amended) An isolated antigenic fusion protein comprising an amino acid sequence of SEQ ID NO: 4 or a fragment thereof and a heterologous carrier protein that induces an anti-IgE immune response that does not cause anaphylaxis when administered to an animal.

41. (Amended) A pharmaceutical kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of claim 7 or 9.